Eosinophilic Biomarker Found for Aggressive IBD
|
By LabMedica International staff writers Posted on 14 Dec 2017 |
|
Image: Peripheral bloods smear showing five eosinophils, from a patient with eosinophilia (Photo courtesy of the Hospital for Sick Children, Toronto).
Peripheral blood eosinophilia (PBE) in inflammatory bowel disease is associated with ulcerative colitis (UC) and active disease. Little data exist on the long-term impact of PBE on disease course.
Inflammatory bowel disease (IBD) is a term mainly used to describe two conditions: ulcerative colitis and Crohn's disease. Ulcerative colitis and Crohn's disease are long-term conditions that involve inflammation of the gut. Ulcerative colitis only affects the colon or large intestine.
A large group of medical scientists working with the University of Pittsburgh Medical Center (Pittsburgh, PN, USA) performed a registry analysis of a consented, prospective, natural history IBD cohort at a tertiary center from 2009 to 2014. Demographics, comorbidities, disease activity, healthcare utilization, and time to hospitalization or surgical resection of patients who displayed PBE were compared to patients without PBE.
The team reported that of the 2,066 IBD patients, 19.2% developed PBE. PBE was significantly associated with UC, extensive colitis, and shorter disease duration. Over six years, PBE patients had more active disease, concurrent C-reactive protein elevation, healthcare utilization (hospitalization and IBD surgery), and more aggressive medical therapy (prednisone and anti- tumor necrosis factor). Patients with PBE had a significantly reduced time to hospitalization in both UC and Crohn’s disease (CD) and reduced time to colectomy in UC. PBE remained significantly associated with hospitalization and surgery in both CD and UC. New diagnosis of UC with PBE was associated with increased steroid and anti- tumor necrosis factor requirement.
The authors concluded that the multi-year study of a large IBD cohort suggests that peripheral blood eosinophilia represents a biomarker of a distinct IBD subgroup, with a unique inflammatory signature, and at risk for worse clinical outcomes. The study was published on November 7, 2017, in The American Journal of Gastroenterology.
Related Links:
University of Pittsburgh Medical Center
Inflammatory bowel disease (IBD) is a term mainly used to describe two conditions: ulcerative colitis and Crohn's disease. Ulcerative colitis and Crohn's disease are long-term conditions that involve inflammation of the gut. Ulcerative colitis only affects the colon or large intestine.
A large group of medical scientists working with the University of Pittsburgh Medical Center (Pittsburgh, PN, USA) performed a registry analysis of a consented, prospective, natural history IBD cohort at a tertiary center from 2009 to 2014. Demographics, comorbidities, disease activity, healthcare utilization, and time to hospitalization or surgical resection of patients who displayed PBE were compared to patients without PBE.
The team reported that of the 2,066 IBD patients, 19.2% developed PBE. PBE was significantly associated with UC, extensive colitis, and shorter disease duration. Over six years, PBE patients had more active disease, concurrent C-reactive protein elevation, healthcare utilization (hospitalization and IBD surgery), and more aggressive medical therapy (prednisone and anti- tumor necrosis factor). Patients with PBE had a significantly reduced time to hospitalization in both UC and Crohn’s disease (CD) and reduced time to colectomy in UC. PBE remained significantly associated with hospitalization and surgery in both CD and UC. New diagnosis of UC with PBE was associated with increased steroid and anti- tumor necrosis factor requirement.
The authors concluded that the multi-year study of a large IBD cohort suggests that peripheral blood eosinophilia represents a biomarker of a distinct IBD subgroup, with a unique inflammatory signature, and at risk for worse clinical outcomes. The study was published on November 7, 2017, in The American Journal of Gastroenterology.
Related Links:
University of Pittsburgh Medical Center
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Portable POCT Blood Gas Analyzer
BD100
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Latest Pathology News
- Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
- AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
- 30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
- AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
- AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
- FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
- Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
- Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
Channels
Clinical Chemistry
view channel
Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40
C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more
Simple Whole-Blood Screen Identifies Elevated Bile Acids Linked to Liver Disease
Liver disease can progress silently until treatment options become more limited. Routine blood panels measure markers such as cholesterol, bilirubin, and triglycerides but typically do not include bile... Read more
Routine Urine Protein Testing Identifies Undiagnosed Chronic Kidney Disease
Chronic kidney disease (CKD) is a major cause of mortality worldwide and often progresses silently until advanced stages. Despite the availability of simple urine and blood tests, many cases remain undetected,... Read more
Longitudinal Heart Stress Assessment Improves Prediction of Cardiovascular Outcomes
Accurately predicting cardiovascular disease (CVD) risk in older adults is challenging when assessments rely on single, point-in-time biomarker measurements. Dynamic indicators that reflect evolving cardiac... Read moreMolecular Diagnostics
view channel
Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. Although maturity-onset... Read more
Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read more
Microbiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Pathology
view channel
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read more
Technology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Industry
view channel
AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
Imagene AI has joined the Proscia Ready partner alliance to integrate its hematoxylin and eosin (H&E) screening tools and immunohistochemistry (IHC) image-analysis capabilities with Proscia’s Concentriq... Read more
